



Tehran University of Medical  
Sciences Publication  
<http://tums.ac.ir>

Iran J Parasitol

Open access Journal at  
<http://ijpa.tums.ac.ir>



Iranian Society of Parasitology  
<http://isp.tums.ac.ir>

## Original Article

# Evaluation of In Vitro Cytotoxic and Apoptotic Effects of Miltefosine on the *Toxoplasma gondii* RH Strain

Shahram Khademvatan<sup>1,2</sup>, Elham Yousefi<sup>1,2</sup>, \*Negar Asadi<sup>1,2</sup>, \*Esmail Abasi<sup>1,3</sup>

1. Department of Medical Parasitology and Mycology, Urmia University of Medical Sciences, Urmia, Iran
2. Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran
3. Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Received 16 Mar 2023

Accepted 10 May 2023

### Keywords:

Interferon-gamma;  
Miltefosine;  
Nitric oxide;  
Tachyzoite;  
*Toxoplasma gondii*

### \*Correspondence Email:

asadi.n@umsu.ac.ir;  
e-abasi@razi.tums.ac.ir,  
esmaeilabasi61@gmail.com

### Abstract

**Background:** We aimed to investigate the cytotoxic and apoptotic effects of miltefosine on *Toxoplasma gondii* RH strain by various techniques.

**Methods:** The study was conducted at the Department of Parasitology and Mycology, Urmia University of Medical Sciences, Iran in 2020. Four groups of five BALB/c mice were selected. The cytotoxicity test was conducted by adding miltefosine to *T. gondii* tachyzoites; control tachyzoites received PBS and MTT assay was done on each suspension. For evaluating the Th1-type immune responses, the serum levels of IFN- $\gamma$  and nitric oxide (NO) were assessed in mice after injecting tachyzoites and miltefosine, respectively. The flow cytometry technique was performed on *T. gondii* tachyzoites challenged with IC<sub>50</sub> and IC<sub>90</sub> doses of miltefosine and unchallenged cells. DNA fragments in *T. gondii* tachyzoites were detected by Terminal dUTPnick-end labeling (TUNEL) method.

**Results:** Overall, 256, 64, 32, and 16  $\mu\text{g}$  concentrations of miltefosine, respectively could kill more than 50% of viable *T. gondii* tachyzoites. The infected mice group, treated with miltefosine, significantly produced more IFN- $\gamma$  relative to other groups ( $P < 0.001$ ). Moreover, a significant difference was found in inducible NO synthase between the experimental and control groups ( $P < 0.05$ ). The flow cytometry results demonstrated a concentration-dependent apoptosis rate in tachyzoites incubated with miltefosine, though the necrosis rate was non-significant. DNA fragmentation analysis indicated oligonucleotides (18-200 bp) in tachyzoites treated with 11  $\mu\text{g}$  of miltefosine for 24, 48 and 72 h. However, this pattern was not observed in untreated control microorganisms.

**Conclusion:** Miltefosine could be a favorable candidate for use as a new treatment for toxoplasmosis.



Copyright © 2024 Khademvatan et al. Published by Tehran University of Medical Sciences.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.

(<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited

## Introduction

The intracellular parasite, *Toxoplasma gondii*, is a cosmopolitan apicomplexan protista important in human and veterinary medicines (1-2). It is one of the most significant zoonotic feline gastrointestinal parasites transmitted to humans without the help of intermediate hosts or vectors (3). The protist could virtually propagate in all warm-blooded mammalian species on all continents (4). One-third of the global human population is seropositive for *T. gondii* infection (5).

Sexual replication occurs in the small intestine cells of the definitive hosts (Felidae family), while asexual replication happens in the nucleated cells of almost all warm-blooded animals and humans (1). Humans get the infection through various routes via oocyst-contaminated water, consumption of raw/undercooked meat products containing tissue cysts, and vertical transmission and tissue graft recipients and infected blood supplies (5). In immunocompetent individuals, toxoplasmosis is often a self-limiting mild disease with no pathognomonic symptoms, including fever, malaise, and lymphadenopathy. However, in pregnant women and immunocompromised patients, the infection is clinically significant because it may develop serious consequences such as splenomegaly, pneumonitis, retinochoroiditis, encephalitis, and fetal abortion or fetus birth with physical or mental abnormalities (4). The disease outcome is remarkably reliant on immune functions, the genetic background of the host, and the parasite genotype (6).

The treatment options for toxoplasmosis vary based on age, symptoms, the host's immune status, and the period of pregnancy in which the infection occurs (4). The standard therapy regimens for toxoplasmosis are pyrimethamine combined with sulfadiazine or clindamycin (7). The foremost limitations of these therapeutics reside in their side effects. Pyrimethamine shows antifolate activity and

gives rise to dose-dependent bone marrow suppression that leads to neutropenia and thrombocytopenia. Regarding sulfonamides, hypersensitivity reactions are somewhat commonplace, particularly in AIDS patients. Moreover, anti-*Toxoplasma* medicines are chiefly active against acute infection; thus, it is possible that treated patients still possess the infection in a latent phase (7-8). By virtue of such issues, there is an urgent need to design, formulate and widely evaluate novel therapeutic agents for toxoplasmosis.

Recently, repurposing existing drugs has broadly been emphasized, which facilitates the intricate process of drug discovery process and avoids extra costs (9). Miltefosine, a hexadecyl phosphocholine (HePC), was first introduced as an anticancer agent in the early 1980s (10). Later, it was approved as a therapeutic drug for treating visceral leishmaniasis (VL) due to *Leishmania donovani* in India, antimony-resistant VL infections, cutaneous leishmaniasis in South America, *Trypanosoma* spp. and free-living amoeba infections such as *Acanthamoeba* spp., and the brain-eating amoeba infections such as *Naegleria fowleri* (11-15).

We aimed to address the cytotoxic and apoptotic effects of miltefosine on *T. gondii* RH strain using various techniques.

## Materials and Methods

### Ethical Issues

The study was approved by the Ethics Committee of Urmia University of Medical Sciences, West Azerbaijan Province, Iran (ethical code: IR.UMSU.REC.1397.395).

The study was conducted in 2020 at the Department of Parasitology and Mycology, Urmia University of Medical Sciences, Urmia, Iran.

### Mice and parasites

Laboratory animals were 20 inbred BALB/c mice (five per each group) of 20-25 g weight aged 7-8 weeks. The mice were kept at the

optimum ambient temperature and had accessibility to water and food supplies according to the guidelines of the Ethics Committee of Urmia University of Medical Sciences, West Azerbaijan Province, Iran. Experimental groups were as follows: unchallenged mice treated with miltefosine (Healthy + HePC), challenged mice treated with miltefosine (Toxo + HePC), challenged mice without any treatment (Toxo + No treatment), and negative control receiving only PBS (control). *T. gondii* type I (RH strain) virulent tachyzoites harvested 3-4 days postinoculation (injection of  $1 \times 10^5$  parasites into mice peritoneal cavity) were kept in sterile phosphate-buffered saline (PBS; pH 7.4) containing 100 µg/ml of streptomycin and 100 U/ml of penicillin and were used for intraperitoneal (IP) challenge (16).

#### *Cytotoxicity test by methylthiazol tetrazolium (MTT) assay*

For this aim, 1, 2, 4, 8, 16, 32, 64, 128, 256, and 512 µg/ml concentrations of miltefosine were added to  $1 \times 10^5$  fresh viable *T. gondii* tachyzoites in sterile tubes. The contents were mixed gently and incubated at 37 °C for 6, 24, 48, and 72 h. Subsequently, alive tachyzoites were enumerated by trypan blue staining and light microscopy. The MTT assay was conducted on 200 µl of each suspension. This assay relies on the formation of formazan crystals within the mitochondria of alive cells. The total activity of this organelle is associated with the number of viable cells; therefore, the in vitro cytotoxic effects of drugs can be measured on various cell lines. Briefly, 10 µl of MTT substrate was added to the test and control samples, followed by incubation with 5-8% CO<sub>2</sub> at 37 °C for 24, 48, and 72 h. In the final step, formazan crystals were dissolved by adding 50 µl of dimethyl sulfoxide (DMSO) solution. The absorbance rate was determined at 570 nm (reference filter: 630 nm) by an automated ELISA reader (17-19). Non-viable *Toxoplasma* tachyzoites were calculated by the following formula, where AT refers to the optical density (OD) of the treated well, AB is

the OD of blank well (containing culture medium), and AC implies the OD of negative control (without treatment):

$$\text{Non-viable (\%)} = 100 - \frac{AT - AB}{AC - AB} \times 100$$

The results were expressed as the concentration that inhibited *Toxoplasma* parasite growth by 50% (IC<sub>50</sub>: half maximal inhibitory concentration).

#### *Measurement of IFN-γ*

After four days of the treatment, blood samples were collected from infected mice of all groups, and the serum samples were tested for serum levels of IFN-γ. Sera were isolated by centrifugation (3000 rpm, 5 min), and the serum level of IFN-γ was measured (1) according to the manufacturer's kit protocol (Mouse Interferon gamma ELISA Kit [IFNG; ab100689 USA]).

#### *Flow cytometry analysis*

The flow cytometry technique was performed using Annexin-V to identify the type (apoptosis and necrosis) of the cell death. In brief, 100 µl of binding buffer (0.01 M of HEPES, pH 7.4, 0.14 M of NaCl, and 2.5 mM of CaCl<sub>2</sub>) combined with 5 µl of each FITC-Annexin V conjugate and propidium iodide (PI) were added to  $1 \times 10^5$  *T. gondii* tachyzoites challenged with IC<sub>50</sub> of miltefosine and unchallenged cells. Incubation was performed in the dark at room temperature for 15 min. In the next step, 400 µl of binding buffer was added, and the final analysis was accomplished using a flow cytometry device. The results obtained for 24-, 48-, and 72-h incubation were analyzed by CellQuest™ software (20-21).

#### *Nitric Oxide (NO) assessment*

After four days of the treatment, blood samples were collected from infected mice of all groups, and the serum samples were tested for serum levels of iNOs. Sera were isolated by centrifugation (3000 rpm, 5 min) (22) and the serum level of iNOs was measured according to the manufacturer's kit protocol Mouse iNOS ELISA Kit (ab253219, USA)

### DNA fragmentation

DNA fragments in *T. gondii* tachyzoites can be detected by Terminal dUTP Nick-End Labeling (TUNEL) method (23). Briefly, 2% paraformaldehyde was added to all experimental organisms, being incubated at 20° C for an hour. Following centrifugation, the cells were impregnated in cold permeation solution (0.1% Triton-X100 in 0.1% sodium citrate) for two minutes, and then washed with PBS and finally incubated in TUNEL reaction agent in a dark room at 37 °C for an hour. A cytometer device (Beckman Coulter, California, USA) was used for the detection of dUTP labeling in the damaged sites of DNA. Qualitative and quantitative analyses of the fragmented genomic DNA (gDNA) were performed using agarose gel electrophoresis. In summary, tachyzoites ( $1 \times 10^5$ ) were incubated in a different time (24, 48, and 72 h), and their gDNA was extracted by the DNA ladder kit

(DNA Fragmentation Kit. Cat. #6137.Takara, Japan), based on manufacturer's protocol. A volume of 10 µg of DNA was loaded on 1.5% agarose gel, and following the electrophoresis (100 V, 2 h), the results were shown in a UV illuminator.


### Data processing and statistical analysis

Results were analyzed by descriptive statistics and non-parametric tests such as Kruskal-Wallis and Mann-Whitney U. A  $P < 0.05$  was considered statistically significant. All statistics were conducted using SPSS 19 software (IBM Corp., Armonk, NY, USA).


## Results

### MTT test

Miltefosine at concentrations of 256, 64, 32, and 16 µg could kill more than 50% of viable *T. gondii* tachyzoites (Fig. 1A, B, and Fig. 2A, B).



**Fig. 1:** In vitro infection and the effect of miltefosine on *T. gondii* tachyzoites after (A)6 and (B)24h of incubation



**Fig.2:** In-vitro infection and the effect of miltefosine on *T.gondii* tachyzoites after (C)48, and (D)72 h of incubation

**Evaluation of IFN-γ production**

The infected mouse group treated with miltefosine significantly produced more IFN-γ compared to other mouse groups ( $P < 0.001$ ).

**Flow cytometry**


A concentration-dependent apoptosis rate was observed in tachyzoites after 24-, 48-, and 72-h incubation with miltefosine; however, the necrosis rate was insignificant. The apoptosis

IC<sub>50</sub> for different incubation periods were as follows: 15.53% (24 h), 47.99% (48 h), and 81.25% (72 h). The detailed results of the flow cytometry analysis are provided in Table 1. Also, the maximum apoptosis rates of the treatment with miltefosine after 48 h (B) and 72 h (C) post-treatment of *T. gondii* RH strain were 56.57% and 86.47%, respectively (Fig. 3A,B,C).

**Table 1:** Apoptosis and necrosis rates observed in tachyzoites after 24-, 48-, and 72-h incubation with miltefosine

Concentration (mg/ml) Time (h)	IC <sub>50</sub>				IC <sub>90</sub>			
	Apoptosis (%)		Necrosis (%)		Apoptosis (%)		Necrosis (%)	
	Control	Miltefosine	Control	Miltefosine	Control	Miltefosine	Control	Miltefosine
24	9.47	15.53	0.48	0.03	13.58	27.27	0.14	0.20
48	43.43	47.99	7.08	10.90	57.00	65.23	2.97	1.74
72	66.03	81.25	9.76	8.35	70.34	91.58	4.40	4.64

IC<sub>50</sub>, half maximal inhibitory concentration; IC<sub>90</sub>, the concentration inhibiting 90% of the organism



**Fig.3:** (A,B,C). Flow cytometry results. (A): Control. Maximum apoptosis rates of the treatment with miltefosine after 48 h (B) and 72 h (C) post-treatment of *T. gondii* RH strain

#### Nitric oxide test

There was a significant difference in the level of inducible NO synthase (iNOS) between the experimental and control groups ( $P < 0.05$ ); the highest iNOS level was found in the tachyzoite-infected group receiving miltefosine (Toxo + HePC). Also, the difference among the groups, Toxo + HePC, Toxo + No treatment, healthy + HePC, and control, was statistically significant ( $P < 0.001$ ).

#### DNA fragmentation

The analysis of DNA fragmentation pattern using 1.5% agarose gel electrophoresis indicated that oligonucleotides (18-200 bp) in tachyzoites were treated with 11  $\mu\text{g}$  of miltefosine for 24 h, though this pattern was not observed in untreated control organisms. In addition, the DNA fragmentation pattern was found in tachyzoites treated after 48 and 72 h.

#### Discussion

Notwithstanding the discovery of the cosmopolitan apicomplexan protist, *T. gondii*, 112 years, several biological aspects of this parasite are still open to question. The parasite readily infects human populations at risk, and there,

regrettably, is no effective therapy without potential side effects to combat clinical infection (24). Thus, an urgent need seems to be essential to recognize novel drug targets in the protozoan organism, design unprecedented drug formulations, and/or repurpose drugs for use against toxoplasmosis. The last one is of the utmost interest such that it remarkably decreases costs and time for drug development, particularly when there is little inducement to invest in *de novo* drug discovery. Considering the side effects of sulfadiazine or clindamycin in the treatment of toxoplasmosis (21) and owing to the promising impacts of miltefosine on cancers and leishmaniasis etc., we used miltefosine instead of the standard therapy regimens, including pyrimethamine combined with sulfadiazine or clindamycin, for toxoplasmosis. The current original study was conducted to appraise the apoptotic and cytotoxic effects of miltefosine on *T. gondii* RH strains in vitro.

Over the past few years, researchers have conducted a multitude of research on miltefosine. In a study, the possible mechanism of miltefosine-mediated death of *L. donovani* promastigotes (in vitro) and of extra- and intra-cellular amastigotes were investigated. The

results indicated that miltefosine could induce apoptosis-like death in *L. donovani* based on the observed phenomena such as nuclear DNA condensation, DNA fragmentation with accompanying ladder formation, and in situ labeling of DNA fragments by the terminal deoxyribonucleotidyl transferase-mediated dUTP-biotin nick end labeling method. They believed that understanding miltefosine-mediated death will facilitate the design of new therapeutic strategies against Leishmania parasites (25). Our results of the inhibitory efficacy of miltefosine on *T. gondii* agrees with the findings achieved by another study where results showed the anti-parasitic activity of miltefosine against *T. gondii* cyst stage in the chronic experimental toxoplasmosis by a significant reduction in the brain cyst burden. Moreover, they detected considerable morphological changes in the cysts by light and electron microscopy and by the amelioration of pathological changes in the brain (26).

In a study on the anti-parasitic effects of miltefosine, Marinho et al. evaluated the action mechanism of miltefosine (as the first effective and safe oral treatment for visceral leishmaniasis) on *L. amazonensis* promastigotes. Miltefosine could induce a process of programmed cell death, which was determined by the externalization of phosphatidylserine, the incorporation of propidium iodide, cell cycle arrest at the sub-G<sub>0</sub>/G<sub>1</sub> phase, and DNA fragmentation into oligonucleosome-sized fragments. They also elucidated that miltefosine gives rise to apoptosis-like death in *L. amazonensis* promastigote cells, as well as in *L. donovani* (27).

Miltefosine caused a dose-dependent apoptotic activity on the Iranian strain of *L. infantum* parasites, with IC<sub>50</sub> of 7 µM after 48-h incubation (28). In the same incubation time and IC<sub>50</sub> of 22 µM and 11 µM, this drug showed cytotoxic properties on *L. tropica* and *L. major* organisms (29). The toxic effect of miltefosine on *L. infantum* has been demonstrated through an apoptosis-associated mechanism in our former investigation in 2011. The

results displayed the dose-dependent death of *L. infantum* by miltefosine and severely increased apoptosis and overexpression of metacaspase and PARP genes six hours after treatment (11).

Similar results to our present study were achieved from Khademvatan et al.'s research work, which studied molecular mechanisms and immunomodulatory properties of miltefosine in the J774 cell line infected with the *L. major* (MRHO/IR/75/ER) parasite. They also utilized RT-PCR and western blotting to assess the gene expression of IFN-γ and to analyze their proteins, respectively. Moreover, cell culture supernatant was examined by ELISA for IL-10 and IL-12 concentrations. Based on their results, in addition to the direct effect, miltefosine could improve cellular immunity with rising IFN-γ and iNOS gene expression, thus activating macrophages (30).

Despite the positive results obtained from the current research, proving the effectiveness of a drug, especially for human use, has its own complications, which should be investigated by conducting clinical trial studies

## Conclusion

More in vivo studies are required to uncover clear evidence of the anti-parasitic activity of miltefosine against *T. gondii* tachyzoites in chronic toxoplasmosis. Meanwhile, drug efficacy against toxoplasmosis depends on the severity of the pathogenicity of different strains of the parasite that needs to be considered. Moreover, using various infection routes can be another area of interest in future studies. We recommend that studies such as those performed on miltefosine can also be conducted on other medications to reduce costs and unwanted side effects of drugs.

## Acknowledgements

This study was financially supported by Urmia University of Medical Sciences, Urmia, Iran (code: 2999) so, the authors wish to

thank Urmia University of Medical Sciences for financing the project.

## Conflict of Interest

The authors declare that they have no conflict of interest.

## References

1. Abasi E, Shahabi S, Golkar M, Khezri P, Hajipirloo HM. Evaluation of immunogenic effect of *Toxoplasma gondii* recombinant SAG-1 antigen with propranolol as adjuvant in BALB/c mice. *Adv Pharm Bull.* 2019;9(4):632-639.
2. Molan A, Nosaka K, Hunter M, Wang W. Global status of *Toxoplasma gondii* infection: systematic review and prevalence snapshots. *Trop Biomed.* 2019;36(4):898-925.
3. Khademvatan S, Abdizadeh R, Rahim F, Hashemitabar M, Ghasemi M, Tavalla M. Stray cats gastrointestinal parasites and its association with public health in Ahvaz City, South Western of Iran. *Jundishapur J Microbiol.* 2014;7(8): e11079.
4. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. *Int J Parasitol.* 2009;39(8):895-901.
5. Saki J, Mohammadpour N, Moramezi F, Khademvatan S. Seroprevalence of *Toxoplasma gondii* in women who have aborted in comparison with the women with normal delivery in Ahvaz, southwest of Iran. *ScientificWorldJournal.* 2015;2015: 764369.
6. Xia J, Cheng X-Y, Wang X-J, Peng H-J. Association between *Toxoplasma gondii* types and outcomes of human infection: a meta-analysis. *Acta Microbiol Immunol Hung.* 2017;64(3):229-44.
7. Paquet C, Yudin MH, Allen VM, et al. Toxoplasmosis in pregnancy: prevention, screening, and treatment. *J Obstet Gynaecol Can.* 2013;35(1):78-81.
8. Weiss LM. *Toxoplasma gondii*: The Model Apicomplexan-Perspectives and Methods Ed. 2: Elsevier Science; 2013.
9. Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing and human parasitic protozoan diseases. *Int J Parasitol Drugs Drug Resist.* 2014;4(2):95-111.
10. Unger C, Peukert M, Sindermann H, Hilgard P, Nagel G, Eibl H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. *Cancer Treat Rev.* 1990;17(2-3):243-6.
11. Khademvatan S, Gharavi MJ, Saki J. Miltefosine induces metacaspase and PARP genes expression in *Leishmania infantum*. *Braz J Infect Dis.* 2011;15(5):442-8.
12. Botero A, Keatley S, Peacock C, Thompson RA. In vitro drug susceptibility of two strains of the wildlife trypanosome, *Trypanosoma copemani*: A comparison with *Trypanosoma cruzi*. *Int J Parasitol Drugs Drug Resist.* 2017;7(1):34-41.
13. Khademvatan S, Gharavi M, Akhlaghi L, et al. Miltefosine Effect on Cell Death of *Leishmania Infantum*. *Intern Med Today.* 2009;15(3):13-20.
14. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: *Balamuthia mandrillaris*, *Acanthamoeba* spp., and *Naegleria fowleri*. *J Eukaryot Microbiol.* 2006;53(2):121-6.
15. Seifert K, Duchêne M, Wernsdorfer WH, et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite *Entamoeba histolytica*. *Antimicrob Agents Chemother.* 2001;45(5):1505-10.
16. Zorgi NE, Costa A, Junior AJG, do Nascimento N, de Andrade Junior HF. Humoral responses and immune protection in mice immunized with irradiated *T. gondii* tachyzoites and challenged with three genetically distinct strains of *T. gondii*. *Immunol Lett.* 2011;138(2):187-96.
17. Khademvatan S, Adibpour N, Eskandari A, Rezaee S, Hashemitabar M, Rahim F. In silico and in vitro comparative activity of novel experimental derivatives against *Leishmania major* and *Leishmania infantum* promastigotes. *Exp Parasitol.* 2013;135(2):208-16.



18. Jazani NH, Karimzad M, Mazloomi E, Sohrabpour M, Hassan ZM, Ghasemnejad H, Roshan-Milani S, Shahabi S. Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed *Listeria monocytogenes* vaccine. *Microbes Infect.* 2010;12(5):382-8.
19. Foroutan-Rad M, Khademvatan S, Jaseem S, Hashemitabar M. Holothuria leucospilota extract induces apoptosis in *Leishmania major* promastigotes. *Iran J Parasitol.* 2016;11(3):339-349.
20. Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. *J Vis Exp.* 2011; (50): 2597.
21. Asadi N, Khademvatan S, Hajipirloo HM, et al. The Cytotoxic and Immunomodulatory Effects of Titanium Dioxide Nanoparticles and Sargassum oligocystum on *Toxoplasma gondii* In Vitro and In Vivo. *Anti Infective Agents.* 2021;19(3):317-24.
22. Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. *Free Radic Biol Med.* 2007;43(5):645-57.
23. Negoescu A, Lorimier P, Labat-Moleur F, et al. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. *J Histochem Cytochem.* 1996;44(9):959-68.
24. Khademvatan S, Saki J, Khajeddin N, et al. *Toxoplasma gondii* exposure and the risk of schizophrenia. *Jundishapur J Microbiol.* 2014;7(11): e12776
25. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of *Leishmania donovani*. *Antimicrob Agents Chemother.* 2004;48(8):3010-5.
26. Eissa MM, Barakat AM, Amer EI, Younis LK. Could miltefosine be used as a therapy for toxoplasmosis? *Exp Parasitol.* 2015;157:12-22.
27. Marinho FdA, Gonçalves KCdS, Oliveira SSd, Oliveira A-CdSCd, Bellio M, d'Avila-Levy CM, Santos ALSd, Branquinha MH. Miltefosine induces programmed cell death in *Leishmania amazonensis* promastigotes. *Mem Inst Oswaldo Cruz.* 2011;106:507-9.
28. Khademvatan S, Gharavi M, Akhlaghi L, Samadikuchaksaraei A, Mousavizadeh K, Hadighi R, Saki J. Induction of Apoptosis by Miltefosine in Iranian Strain of *Leishmania infantum* Promastigotes. *Iran J Parasitol.* 1;4(2):23-31.
29. Khademvatan S, Gharavi MJ, Rahim F, Saki J. Miltefosine-induced apoptotic cell death on *Leishmania major* and *L. tropica* strains. *Korean J Parasitol.* 2011;49(1):17-23.
30. Khademvatan S, Gharavi MJ, Yousefi E, Saki J. INOS and IFN gamma Gene Expression in *Leishmania major*-Infected J774 Cells Treated With Miltefosine. *Int J Pharmacol.* 2011;7(8):843-9.